DEFA14A ·Filed Apr 28, 2026

MRVI

MARAVAI LIFESCIENCES HOLDINGS, INC.
NEUTRAL
Impact 1/10
Horizonimmediate Processed5mo ago SEC0001823239-26-000016
Proxy solicitation materials
Actionable Insight • Neutral

No trading action warranted. This is a purely technical correction to add XBRL tagging. Monitor the actual Annual Meeting on May 26, 2026, for voting outcomes, but no market-moving information is expected from this filing.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
MRVI ▲ +98.03% at T+60d
NEUTRAL call ✓ call won +98.03% · α vs SPY +94.04% · entry $3.56 → $7.05
Entry anchored
Apr 28, 2026
via day open
T+1d
-2.25%
call -2.25% · α -2.24%
$3.48
settled 5mo ago
T+5d
+8.15%
call +8.15% · α +6.45%
$3.85
settled 5mo ago
T+20d
+22.75%
call +22.75% · α +17.30%
$4.37
settled 4mo ago
T+60d
+98.03%
call +98.03% · α +94.04%
$7.05
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Maravai LifeSciences Holdings, Inc. filed a DEFA14A to add Inline XBRL tagging to its definitive proxy statement for the 2026 Annual Meeting of Shareholders, correcting an inadvertent omission. The proxy statement covers the election of three Class III directors (Bernd Brust, Gregory T. Lucier, Luke Marker), ratification of Deloitte & Touche LLP as auditor, and an advisory say-on-pay vote. The filing is purely administrative and contains no new material information.

Key Facts

  • DEFA14A filed solely to add Inline XBRL tagging omitted from original proxy statement
  • No modifications or updates to any disclosures in the original proxy statement
  • Annual Meeting scheduled for May 26, 2026, at 2:30 p.m. Pacific Time, virtual-only format
  • Record date for voting is March 27, 2026
  • Proposals include election of three Class III directors, ratification of Deloitte & Touche LLP, and advisory say-on-pay vote
  • GTCR controls majority of outstanding common stock and has director nomination rights

Financial Impact

No financial impact — filing is administrative correction only

Risk Factors

  • No material risks identified from this administrative filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
59% bullish (17 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001823239-26-000016
Document: 0001823239-26-000016-index-headers.html0001823239-26-000016
Document: 0001823239-26-000016-index.html0001823239-26-000016
Document: 0001823239-26-000016.txt0001823239-26-000016
4 reports for MRVI
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for MRVI — sortable, filterable
TypeNow
Jun 14, 2026
15w ago
Institutional Cluster
MIXED ★ 4/10
$4.96 $6.95▲ +40.12%▲ +39.12%$7.90 (+59.27%)
Jun 3, 2026
17w ago
8-K
BULLISH ★ 6/10
$4.84 $8.37▲ +72.93%▲ +70.44%$7.90 (+63.22%)
Apr 28, 2026
22w ago
DEFA14A
NEUTRAL ★ 1/10
$3.56 $7.05▲ +98.03%▲ +94.04%$7.90 (+121.91%)
Feb 25, 2026
31w ago
8-K
MIXED ★ 6/10
$3.26 $4.43▲ +35.89%▲ +28.94%$7.90 (+142.33%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (64h 16m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access